Market Overview

Myriad Announces Launch of "Go Green" Sustainability Initiative In Support of Earth Day

Share:

SALT LAKE CITY, April 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced the launch of its new Go Green sustainability initiative. As part of the initiative, Myriad is initially focused on promoting increased recycling and reducing material waste used throughout the company. Myriad has now launched several initiatives and employee incentive programs to try and increase its total volume of recyclable materials by over 100% and reduce material waste by 20% by the end of fiscal year 2019. Beyond the initial focus of material waste reduction, the company intends to introduce a number of additional environmental programs over the next several years in areas such as reducing greenhouse gas emissions, reducing water use, reducing power consumption and promoting employee health and safety. 

"I am extremely proud of the launch of the Go Green initiative which is reflective of our values as a company and Myriad's dedication to improving the world which we live in," said Mark C. Capone, president and CEO, Myriad Genetics. "Being a responsible steward is an integral part of the DNA of our company."

As part of Earth Day, Myriad Genetics employees will also be participating in local community service projects including volunteer work at the University of Utah's Red Butte Gardens and facilitating the collection of hard-to-recycle items such as fluorescent light bulbs. Throughout the month of May, employees will also take part in education about waste reduction and look for ways to incorporate sustainable practices into their daily work.

"At Myriad caring is part of who we are as an organization and beyond caring about patients we care deeply for the local community and environment where we work, said Steve Beus, head of the Myriad Go Green Team. "We strongly believe this initiative will have a significant impact on our environmental footprint as a company and benefit the beautiful Utah community in which we work and live."

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on five strategic imperatives:  build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's efforts to increase its total volume of recyclable materials by over 100% and reduce material waste by 20% by the end of fiscal year 2019; the company's intention to introduce a number of additional environmental programs over the next several years in areas such as reducing greenhouse gas emissions, reducing water use, reducing power consumption and promoting employee health and safety; Company employees participating in local community service projects including volunteer work at the University of Utah's Red Butte Gardens, facilitating the collection of hard-to-recycle items such as fluorescent light bulbs, and taking part in education about waste reduction and looking for ways to incorporate sustainable practices into their daily work; this initiative having a significant impact on the Company's environmental footprint and benefiting the Utah community;  and the Company's strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2016, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:       Ron Rogers
(801) 584-3065
rrogers@myriad.com
      Investor Contact:       Scott Gleason
(801) 584-1143
sgleason@myriad.com
             

Primary Logo

View Comments and Join the Discussion!